Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viridian TherapeuticsSTU:1S1 -1.49%52 EBIT per Share is €-3.23 as of Jun. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 52/100. The stock has 5 warning signs investors should review. Among 1,167 Biotechnology companies, Viridian Therapeutics ranks worse than 70.44% on this metric.
Viridian Therapeutics's EBIT per Share for the
three
months ended in Jun. 2026 was €-0.96.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €-3.23.
During the past 3 years, the average EBIT per Share Growth Rate was -0.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 33.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Viridian Therapeutics's EBIT per Share or its related term are showing as below:
STU:1S1'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -80.3 Med: 20.7 Max: 69
Current: -0.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Viridian Therapeutics was 69.00% per year. The lowest was -80.30% per year. And the median was 20.70% per year.
STU:1S1's 3-Year EBIT Growth Rate is ranked worse than 70.44% of 1167
companies
in the Biotechnology industry
Industry Median: 15.5
vs STU:1S1: -0.80
Viridian Therapeutics (STU:1S1) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Viridian Therapeutics EBIT per Share Related Terms
Viridian Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (STU:1S1) has a EBIT per Share of €-3.23 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Viridian Therapeutics and its competitors. According to the industry distribution chart, Viridian Therapeutics ranks #822 out of 1167 companies in the Biotechnology industry, placing it in the top 70.4%.
Is Viridian Therapeutics' EBIT per Share too high?
Viridian Therapeutics' current EBIT per Share is €-3.23. Based on the distribution chart, Viridian Therapeutics ranks #822 out of 1167 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' EBIT per Share compare to BHVN and AGIO?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #822 out of 1167 companies for EBIT per Share. This places Viridian Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Viridian Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viridian Therapeutics's current EBIT per Share is €-3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (STU:1S1) has a current EBIT per Share of €-3.23. The current EBIT per Share is €-3.23. Viridian Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current EBIT per Share is €-3.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
52GF Score
Get the complete analysis for STU:1S1
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1S1 has been successfully added to your 
